Cognition Therapeutics Inc (CGTX) stock saw a modest uptick, ending the day at $0.65 which represents a slight increase of $0.04 or 6.56% from the prior close of $0.61. The stock opened at $0.61 and ...

On Friday, Cognition Therapeutics Inc (CGTX) stock saw a modest uptick, ending the day at $0.63 which represents no change from the prior close of of $0.63. The stock opened at $0.64 and touched a low ...

B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up ...

Fintel reports that on December 19, 2024, B. Riley Securities upgraded their outlook for Cognition Therapeutics ...

B. Riley upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a $1.50 price target Pick the best stocks and maximize your ...

H.C. Wainwright raised the firm’s price target on Cognition Therapeutics (CGTX) to $6 from $5 and keeps a Buy rating on the shares. The company ...

Traders wasted no time buying up shares of Cognition Therapeutics, Inc. (Nasdaq:CGTX), with the current bid sitting at ...

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market. Shanghai-based Hansoh Pharmaceutical Group Co. Ltd. has licensed HS-10535, an investigational preclinical oral small ...

Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body ...

Cognition Therapeutics' CT1812 improves dementia with Lewy bodies outcomes, reducing anxiety, hallucinations, and functional ...

Given this risk, we thought we'd take a look at whether Cognition Therapeutics (NASDAQ:CGTX) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...